New drug candidate found for hand, foot and mouth disease

The compound of interest is a small molecule that binds to RNA and the virus's genetic material, and it changes its 3D shape in a way that stops the virus from multiplying without harming its human host.

There are currently no FDA-approved drugs or vaccines for enterovirus 71, which affects hundreds of thousands of children each year, particularly in Southeast Asia. While most people get better within 7 to 10 days after suffering little more than a fever and rash, severe cases can cause brain inflammation, paralysis and even death.

A study offers some good news in the search for antiviral drugs for hard-to-treat diseases. Researchers have identified a potential new drug candidate against enterovirus 71, a common cause of hand, foot and mouth diseases in infants and young children.

“The work could pave the way for new treatments for other viral infections as well”, said a team of scientists from Duke University, Case Western Reserve University and Rutgers University.



Probe-Medicine & Medical Science is an international, open-access journal which is designed for all doctors, researchers, and health workers and it aims to promote communication among clinical researchers worldwide.

It includes the fields of Anaesthesia, Bioengineering, Biomedical Sciences, Dermatology, Epidemiology and Public Health, Health Informatics, History of Medicine, Health Plan and Administration, Medicine, Neurological Sciences, Ophthalmology, Obstetrics.

It accepts original research articles, review articles, case reports and short communications. We sincerely welcome submissions from everyone.

For more information, please visit: